Jeaustin Arón Mora

Dr. Jeaustin Arón Mora


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Dermato
Verified
Journal Article
Open access
PDF file
EMErnesto Martínez-Vargas
Ernesto Martínez-Vargas
JMJeaustin Arón Mora
Jeaustin Arón Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JHJosephine Hernández-López
Josephine Hernández-López
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Background: Artificial intelligence (AI) has emerged as a transformative tool in modern medicine, particularly in dermatology, where it supports the diagnosis and management of various skin diseases, including skin cancer. Through machine learning and deep learning techniques, AI enables accurate analysis of clinical and dermoscopic images, improving early detection and clinical outcomes. Objective: This systematic review aimed to evaluate the clinical applications of AI in dermatology, focusing on its impact on diagnostic accuracy, workflow efficiency, and access to specialized care. Methods: The review was conducted according to PRISMA guidelines. Peer-reviewed studies published between January 2020 and March 2025 in English or Spanish were included if they evaluated AI-based tools for dermatological diagnosis, classification, or treatment. Animal studies, editorials, non-peer-reviewed articles, and studies with an unclear methodology were excluded. A comprehensive search was performed in PubMed, Scopus, IEEE Xplore, and Google Scholar between December 2024 and March 2025. The risk of bias was assessed qualitatively, using a tailored framework based on study design, dataset transparency, and clinical applicability. Results: A total of 29 studies met the inclusion criteria. AI tools demonstrated high performance in melanoma detection, achieving up to 90% accuracy and 85% sensitivity. In clinical settings, AI support reduced mismanagement of malignant lesions from 58.8% to 4.1% and avoided 27% of unnecessary procedures in benign cases. Additional tools such as convolutional neural networks and imaging systems like FotoFinder also showed promising results. Limitations: Limitations of the evidence include the heterogeneity of AI models, lack of external validation, and a moderate-to-high risk of bias. Conclusions: AI has demonstrated robust clinical potential in dermatology, particularly in cancer detection and workflow optimization. However, further studies are required to address challenges such as algorithmic bias, data privacy, and regulatory oversight. Funding and registration: This review received no external funding and was not registered in a systematic review registry.

9 July 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
AAAndrés Alvarado-Calvo
Andrés Alvarado-Calvo
YAYazlin Alvarado-Rodríguez
Yazlin Alvarado-Rodríguez
KMKevin José Cruz Mora
Kevin José Cruz Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Background/Objectives: Climate change is a major factor exacerbating non-communicable diseases (NCDs) such as cardiovascular diseases, neoplasms, respiratory diseases, and diabetes, especially in vulnerable Latin American regions. This study analyzes the impact of environmental exposures related to climate change on the NCD burden in eight Latin American countries by quantifying the disability-adjusted life years (DALYs) attributable to these factors. Using Global Burden of Disease (GBD) data (1990–2021), we performed multiple linear regression to assess associations between DALYs and environmental risk factors—air pollution (particulate matter, nitrogen dioxide), radon, lead, and extreme temperatures—in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, Peru, and Uruguay. The study included major NCDs, and the population was stratified by age and sex. Results: Ischemic heart disease was the leading cause of DALYs in most countries. Particulate matter pollution was the main environmental risk factor contributing to the NCD burden, mainly affecting cardiovascular and respiratory diseases. Mexico showed the highest DALYs from particulate and ozone pollution; temperature and lead exposure also contributed in some countries. Nitrogen dioxide was the primary risk factor for asthma. Statistically significant relationships between environmental factors and DALYs were confirmed. Conclusions: Climate change-related exposures significantly increase the burden of NCDs in Latin America. Targeted interventions in industry, transportation, and energy, along with sustainable urban policies, are essential to mitigate health impacts and reduce disparities. Integrating environmental health into public policies can improve health outcomes amid ongoing climate challenges.

18 January 2026 in International Medical Education
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
AOAngie Ortiz-Ureña
Angie Ortiz-Ureña
LHLuis Esteban Hernández-Soto
Luis Esteban Hernández-Soto
JMJeaustin Arón Mora
Jeaustin Arón Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
Background: Artificial intelligence (AI) is reshaping health sciences education worldwide, yet regional data from Latin America remain scarce. Understanding students’ AI literacy and perceptions is essential for developing informed curricular strategies. Methods: A cross-sectional online survey was conducted among 270 students from four Costa Rican universities across five health sciences programs. Descriptive and inferential analyses (ANOVA, Chi-square) examined AI knowledge, usage frequency, and perceptions of ethical integration in academic contexts. Results: Over 80% of respondents reported moderate or higher AI knowledge and frequent use of tools such as ChatGPT, mostly for academic support tasks. However, more than 90% had not received formal institutional training, and ethical awareness—particularly regarding misinformation and bias—was limited. Conclusions: Students demonstrate active engagement with AI despite minimal curricular exposure. These findings emphasize the need for structured AI training, faculty development, and equitable access policies aligned with global digital ethics frameworks to ensure responsible adoption within Costa Rican health sciences education.

15 January 2026 in Dermato
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
ACAudry Escudero Correa
Audry Escudero Correa
JMJeaustin Arón Mora
Jeaustin Arón Mora
AHAndy Hernández
Andy Hernández
LMLuis Carlos Monge-Bogantes
Luis Carlos Monge-Bogantes
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
Background/Objectives: Acute generalized exanthematous pustulosis (AGEP) is a severe drug-induced cutaneous reaction characterized by the abrupt onset of sterile pustules, fever, neutrophilia, and a T cell-mediated type IVd hypersensitivity response. This narrative review synthesizes current evidence on pharmacological triggers, immunopathogenic mechanisms, diagnostic criteria, and differential diagnosis to provide a clinically oriented framework. Methods: A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, ScienceDirect, and SpringerLink for studies published between 2000 and 2025, complemented by selected clinical reference sources. Studies addressing clinical features, immunological pathways, pharmacovigilance signals, and diagnostic tools for AGEP were included. Synthesis of Evidence: β-lactam antibiotics remain the most frequent triggers, while increasing associations have been reported with hydroxychloroquine, targeted therapies, immune checkpoint inhibitors, psychotropic agents, and vaccines. Immunopathogenesis is driven by IL-36 activation, CXCL8/IL-8–mediated neutrophil recruitment, and IL36RN mutations, explaining overlap with pustular psoriasis. Diagnostic accuracy improves through integration of drug latency, clinical morphology, histopathology, biomarkers, and standardized tools such as the EuroSCAR score. Conclusions: AGEP is a complex pustular reaction induced by diverse drugs and amplified by IL-36-mediated inflammation. Accurate diagnosis requires a multidimensional approach supported by structured algorithms and robust pharmacovigilance to identify evolving drug-associated patterns.

13 March 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JMJeaustin Arón Mora
Jeaustin Arón Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.

16 July 2025 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
EMErnesto Martinez-Vargas
Ernesto Martinez-Vargas
JMJeaustin Arón Mora
Jeaustin Arón Mora
KMKevin José Cruz Mora
Kevin José Cruz Mora
JVJorge Arturo Villalobos-Madriz
Jorge Arturo Villalobos-Madriz